KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to $28.6 million.

  • Nektar Therapeutics' Accumulated Expenses fell 1168.42% to $28.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.6 million, marking a year-over-year decrease of 1168.42%. This contributed to the annual value of $30.0 million for FY2024, which is 3524.05% up from last year.
  • Nektar Therapeutics' Accumulated Expenses amounted to $28.6 million in Q3 2025, which was down 1168.42% from $35.1 million recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Accumulated Expenses registered a high of $37.4 million during Q1 2023, and its lowest value of $15.7 million during Q4 2021.
  • For the 5-year period, Nektar Therapeutics' Accumulated Expenses averaged around $28.6 million, with its median value being $29.5 million (2024).
  • As far as peak fluctuations go, Nektar Therapeutics' Accumulated Expenses surged by 13232.92% in 2022, and later crashed by 3937.69% in 2023.
  • Quarter analysis of 5 years shows Nektar Therapeutics' Accumulated Expenses stood at $15.7 million in 2021, then skyrocketed by 132.33% to $36.6 million in 2022, then plummeted by 39.38% to $22.2 million in 2023, then soared by 35.24% to $30.0 million in 2024, then dropped by 4.6% to $28.6 million in 2025.
  • Its last three reported values are $28.6 million in Q3 2025, $35.1 million for Q2 2025, and $31.3 million during Q1 2025.